Tesamorelin vs MK-677
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.
Also: Ibutamoren, Nutrobal
MK-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. Taken as a daily pill, it reliably pushes up growth hormone and IGF-1 levels, which is why it is popular for muscle and recovery. It has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and Alzheimer's came up short.
Key Comparison Insights
- Tesamorelin is FDA approved, while MK-677 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to MK-677 (Human Trials).
Detailed Comparison
| Attribute | Tesamorelin | MK-677 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies. | MK-677 is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor the hormone ghrelin binds. By activating that receptor in the pituitary and hypothalamus, it triggers pulses of growth hormone release, which in turn raises IGF-1 (insulin-like growth factor 1) from the liver. Because it copies ghrelin, it also tends to increase appetite, and it can nudge up cortisol levels too. The effect is sustained because it is long-acting and orally available, unlike injectable peptides that mimic ghrelin or growth-hormone-releasing hormone. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | 10-25 mg daily Once daily, often before bed |
| Administration | Subcutaneous injection | Oral |
| Typical Duration | Indefinite for approved indication | 8-12 weeks or longer |
| Best Time to Take | Before bed (fasted) | Before bed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The approval rests on real randomized, placebo-controlled human trials. The pivotal study by Falutz and colleagues (New England Journal of Medicine, 2007) showed that six months of tesamorelin selectively reduced visceral abdominal fat in HIV patients while improving lipid profiles, without meaningful harm to blood sugar control. Later randomized work (including a JAMA-published trial led by Stanley) confirmed reductions in visceral fat and liver fat. A small placebo-controlled study in non-HIV adults with abdominal obesity also found a meaningful visceral fat reduction over 26 weeks, hinting at broader potential, though that is far less established than the HIV indication. Side effects can include joint pain, swelling, and increases in IGF-1, and growth-hormone-axis drugs warrant caution in people with cancer history or uncontrolled diabetes. In short: well proven for HIV-associated visceral fat, promising but not approved for general use. | MK-677 has unusually good human data for a compound sold in the gray market, and the data is a mix of clear wins and clear failures. In a one-year randomized trial of 65 healthy older adults (Annals of Internal Medicine, 2008), 25 mg daily raised IGF-1 and increased fat-free mass, basically lean tissue, though much of the early body-weight gain was water and the functional strength benefits were not impressive. In Alzheimer's disease, a large 563-patient, 12-month randomized trial (Neurology, 2008) confirmed it raised IGF-1 but did nothing to slow cognitive decline. Across studies the consistent downsides are increased appetite, fluid retention, and reduced insulin sensitivity (higher blood sugar). So the muscle-and-IGF-1 effect is real and well documented, but MK-677 failed its biggest disease trials, remains unapproved, and is banned in sport by WADA. |
Frequently Asked Questions: Tesamorelin vs MK-677
What is the difference between Tesamorelin and MK-677?
Tesamorelin is a growth hormone peptide that tesamorelin is a stabilized analog of growth-hormone-releasing hormone (ghrh 1-44) with a chemical modification that protects it from rapid breakdown. it is fda-approved (brand name egrifta) to reduce excess visceral abdominal fat in people with hiv-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online. MK-677 is a growth hormone peptide that mk-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. taken as a daily pill, it reliably pushes up growth hormone and igf-1 levels, which is why it is popular for muscle and recovery. it has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and alzheimer's came up short. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or MK-677?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while MK-677 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and MK-677 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and MK-677 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.